Creative Biolabs has established a universal antibody humanization platform to develop high affinity human monoclonal antibodies derived from non-human primates (NHPs). This platform, known as Hi-Affi™ human antibody platform, can offer higher affinity antibodies than humanized antibodies originated from other species, such as widely used murine antibodies.
Human monoclonal antibody (mAbs) are emerging in the field of cancer therapy and have become an increasing proportion of new drugs that are recently approved. Although there are some methods to obtain antigen-specific mAbs from human B cells, it is generally impossible to directly immunize human beings with antigens of interest. For example, for infectious agents, those approaches are largely restricted. To solve these obstacles, two main approaches have been developed; either by humanizing antigen-specific antibodies from small experimental animals (which is laborious due to the great genetic differences from humans) or rely on the in vitro selection of antigen-specific binders from human antibody repertoires. However, the human mAbs developed by these methods are usually with low affinity.
We are now coming up with a much better idea that is humanizing non-human primates mAbs instead of murine mAbs. Due to the close genetic relationship with humans, immunized NHPs have more potential to be isolated with high affinity antibodies to human target than other experimental species, such as mouse, rat and rabbit. In addition, with appropriate method, NHP antibodies are much easier to be humanized without any loss of affinity compared to widely used murine antibodies.
Creative Biolabs is expert in humanizing monoclonal antibodies derived from a wide range of species including mouse, rat, dog and non-human primates. With years of experience in humanization and monoclonal antibody research, our scientists are professional to provide highly specific and affinity improved human monoclonal antibodies.
Fig.1 From chimeric to humanized antibody. (Jones et al. 1986)